Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
NCT07518043Phase 1Recruiting
- Sponsor
- Henlius
- Start
- Jul 2026
- Primary completion
- Aug 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HLX18 in esophageal cancer, gastroesophageal junction cancer, melanoma and 1 more (2 arms), sponsored by Henlius. Primary endpoints: Area Under the Curve from time 0 to 28 days and Area Under the Curve at steady state at 16 weeks. Started Jul 2026; status: recruiting.
02
Drugs
HLX18
03
Conditions
esophageal cancergastroesophageal junction cancermelanomaurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT07518043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07518043.